Jessica N. Abraham | Designer. Writer. Publicist.

19+ Years of Expertise in Digital Marketing, Social Branding and Public Relations.

  • Home
  • Contact
  • About
  • Home
  • Contact
  • About

No Widgets found in the Sidebar Alt!

  • Statera Pharmaceuticals treatment for Covid-19 Long-Haulers
    Health,  Benzinga,  Biotechnology,  Business,  Finance

    Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

    October 28, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…

    read more
    Jessica N. Abraham Comments Off on Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

    You May Also Like

    industrial Hemp, Generation Hemp, GENH, Hemp, Cannabis, Textiles, Manufacturing,

    Why Is There a Renewed Interest in Hemp by Textile and Manufacturing Companies?

    August 6, 2021
    Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022
    Age-Related Macular Degeneration DRY AMD, Lineage Cell Therapeutics

    Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?

    August 11, 2021
  • Statera Biopharmaceuticals, Groundbreaking Biomedicine Treatment
    Health,  Benzinga,  Biotechnology,  Business,  Finance

    Statera BioPharma: The Ticker Formerly Known as CBLI

    September 7, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets.  This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health — including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases.  The company began trading as CLBI, last month,…

    read more
    Jessica N. Abraham Comments Off on Statera BioPharma: The Ticker Formerly Known as CBLI

    You May Also Like

    Smart Buildings, HVAC, Indoor Air Quality, WiFi, Connected Devices, Internet of things, IoT,

    Delphi360™ to Officially Launch, Improve the Work Environment and Change Indoor Air Quality Forever

    September 7, 2021
    Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022
    Hemp-based animal bedding for small animals and farms -- pest free, pesticide free, mold-free, antibacterial, safe, edible.

    Industrial Hemp: Big Win for Pet Stores, Farmers, and Animals

    October 25, 2021
  • Business
  • Technology
  • Career Development
  • Education
  • Entertainment
  • Fashion
  • Relationships
  • Tips
  • Travel
Ashe Theme by WP Royal.